Rapid Spread of Drug-Resistant Fungus C. auris in European Hospitals
New findings reveal that the drug-resistant fungus Candida auris is rapidly spreading across European hospitals, posing a significant threat to patient safety and infection control efforts. Early detection and coordinated response are crucial to stopping its spread.
Recent findings from the European Centre for Disease Prevention and Control (ECDC) confirm that Candida auris (formerly known as Candida auris), a multidrug-resistant fungus, is rapidly proliferating within hospitals across Europe. This is the fourth comprehensive survey indicating a concerning increase in cases, highlighting a significant threat to patients and public health systems.
The latest data show a worrying rise in case numbers, with many outbreaks expanding significantly, and several countries experiencing ongoing local transmission. Notably, the fungus’s ability to persist on various surfaces and medical equipment, coupled with its resistance to many antifungal medications, makes controlling its spread extremely challenging.
Between 2013 and 2023, over 4,000 cases have been reported across the EU/EEA countries. In 2023 alone, there were 1,346 recorded cases in 18 countries. Spain, Greece, Italy, Romania, and Germany have been the most affected, accounting for the majority of cases over the past decade.
Experts from the ECDC emphasize that while the situation is serious, early detection and strengthened infection control protocols can still mitigate further spread. Recent outbreaks in Cyprus, France, and Germany, alongside widespread regional transmission in Greece, Italy, Romania, and Spain, underscore the critical need for coordinated response efforts.
Despite some countries making progress in outbreak management, many lack comprehensive national surveillance systems—only 17 out of 36 countries currently monitor C. auris cases systematically. Additionally, just 15 countries have specific infection prevention and control guidance, while laboratory capacity for identifying the fungus varies, with many countries lacking the necessary facilities for effective detection.
The true extent of the problem is likely underestimated due to inconsistent reporting. The ECDC continues to assess the epidemiological situation, aiming to bolster national preparedness and response strategies. Improved surveillance, early case detection, and effective infection control guidelines are essential to prevent further dissemination of this dangerous pathogen.
Source: https://medicalxpress.com/news/2025-09-drug-resistant-fungus-auris-rapidly.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
promising treatment for severe post-COVID syndrome in children using celiac disease drug
A groundbreaking study reveals that an experimental drug for celiac disease shows promise in treating severe post-COVID syndrome in children, offering new hope for MIS-C recovery.
Persistent Risks of Death and Complications from Broken Heart Syndrome (2016-2020)
Recent studies reveal that the risk of death and major complications from broken heart syndrome remained high in the U.S. from 2016 to 2020, highlighting critical needs for improved diagnosis and management.
Experts Warn Menopause Misinformation Is Compromising Women's Care
Experts warn that misinformation and unnecessary hormone testing are harming menopause care, emphasizing the need for evidence-based practices and clinical diagnosis.
Hearing Aids and Cochlear Implants Boost Social Connection and Quality of Life
Hearing aids and cochlear implants significantly enhance social engagement and reduce isolation in adults with hearing loss, promoting better overall well-being.